Ceftolozane-tazobactam

سفتولوزان-تازوباکتام

⚠ Unverified

🦠 Antiinfectives For Systemic UseCephalosporin + beta-lactamase inhibitor

Market / country: 🇺🇸 USA

Zerbaxa (US)

🧮 Dose calculator

Complicated intra-abdominal infection and peritonitis · Regimen source: FDA Zerbaxa · 2.1, Table 1

  • • Dose as total ceftolozane + tazobactam (2:1). 1-hour infusion every 8 h. cIAI with metronidazole. FDA Zerbaxa · 2.1

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

  • ⛔ Serious hypersensitivity to ceftolozane, tazobactam, piperacillin-tazobactam or other beta-lactams. FDA Zerbaxa · 4

Warnings

  • • Decreased efficacy with baseline CrCl 30–50; hypersensitivity; C. difficile diarrhoea; drug-resistant bacteria. FDA Zerbaxa · 5

Renal adjustment

  • • eGFR < 51: CrCl ≤50: cIAI/cUTI 30–50 → 750 mg, 15–29 → 375 mg every 8 h; pneumonia 30–50 → 1.5 g, 15–29 → 750 mg; ESRD per Table 3. FDA Zerbaxa · 2.3, Table 3

Formulations

  • 1.5 g vial (ceftolozane 1 g + tazobactam 0.5 g) — powder for injection 🇺🇸 USA FDA Zerbaxa · 3

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Zerbaxa · 8.1

    “Risk Summary There are no data available on ZERBAXA, ceftolozane or tazobactam use in pregnant women to allow assessment of a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Zerbaxa · 8.2

    “Risk Summary There are no data on the presence of ceftolozane or tazobactam in human milk.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Zerbaxa · 8.4

    “The safety and effectiveness of ZERBAXA for the treatment of cIAI, cUTI, and HABP/VABP have been established in pediatric patients at least 32 weeks gestational age and older.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Zerbaxa · 8.5

    “Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.”
  • ⚥ Females & males of reproductive potentialNo data

    The source for this drug has no section for this group.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav